A Fluorometric Method of Measuring Carboxypeptidase Activities for Angiotensin II and Apelin-13

Scientific Reports

Volumn 7, Issue , 2017, Pages

  Liu, Pan ^a   Wysocki, Jan ^a   Serfozo, Peter ^a   Ye, Minghao ^a   Souma, Tomokazu ^a   Batlle, Daniel ^a   Jin, Jing ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN CONVERTING ENZYME 2; ANGIOTENSIN I; ANGIOTENSIN I (1-7); ANGIOTENSIN II; APELIN-13 PEPTIDE; CARBOXYPEPTIDASE; DIPEPTIDYL CARBOXYPEPTIDASE; PEPTIDE FRAGMENT; PHENYLALANINE; SIGNAL PEPTIDE;

AMINO ACID SEQUENCE; ANIMAL; ENZYME SPECIFICITY; ENZYMOLOGY; FLUOROMETRY; HEK293 CELL LINE; HUMAN; IMMUNOASSAY; KIDNEY; METABOLISM; MOUSE;

AMINO ACID SEQUENCE; ANGIOTENSIN I; ANGIOTENSIN II; ANIMALS; CARBOXYPEPTIDASES; FLUOROMETRY; HEK293 CELLS; HUMANS; IMMUNOASSAY; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; KIDNEY; MICE; PEPTIDE FRAGMENTS; PEPTIDYL-DIPEPTIDASE A; PHENYLALANINE; SUBSTRATE SPECIFICITY;

EID: 85017002157     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep45473     Document Type: Article

References (48)

1. Seva Pessoa, B., et al. Key developments in renin-angiotensin-aldosterone system inhibition. Nat Rev Nephrol 9, 26-36, doi: 10. 1038/nrneph. 2012. 249 (2013).
2. Bader, M. Tissue Renin-Angiotensin-Aldosterone Systems: Targets for Pharmacological Therapy. Annual Review of Pharmacology and Toxicology 50, 439-465, doi: 10. 1146/annurev. pharmtox. 010909. 105610 (2010).
3. Hiroyuki, K., Hirohito, M., Tsutomu, M. , Akira, N. Angiotensin II Blockade and Renal Protection. Current Pharmaceutical Design 19, 3033-3042, doi: 10. 2174/1381612811319170009 (2013).
4. Gorski, T. P. , Campbell, D. J. Angiotensin-converting enzyme determination in plasma during therapy with converting enzyme inhibitor: Two methods compared. Clinical Chemistry 37, 1390-1393 (1991).
5. Friedland, J. , Silverstein, E. A Sensitive Fluorimetric Assay for Serum Angiotensin-con venrting Enzyme. American Journal of Clinical Pathology 66, 416-424, doi: 10. 1093/ajcp/66. 2. 416 (1976).
6. Matucci-Cerinic, M., et al. Clinical correlations of plasma angiotensin converting enzyme (ACE) activity in systemic sclerosis: A longitudinal study of plasma ACE level, endothelial injury and lung involvement. Respiratory Medicine 84, 283-287, doi: 10. 1016/S0954-6111(08)80054-6 (1990).
7. Costabel, U. , Teschler, H. Biochemical changes in sarcoidosis. Clin Chest Med 18, 827-842 (1997).
8. Baudin, B. New aspects on angiotensin-converting enzyme: From gene to disease. Clin Chem Lab Med 40, 256-265, doi: 10. 1515/CCLM. 2002. 042 (2002).
9. Danilov, S. M., et al. Conformational Fingerprinting of the Angiotensin I-Converting Enzyme (ACE). Application in Sarcoidosis. Journal of Proteome Research 9, 5782-5793, doi: 10. 1021/pr100564r (2010).
10. Wysocki, J., Wilsbacher, L. , Batlle, D. Angiotensins and the Heart. Is Angiotensin-(1-7) Cardioprotective Hypertension 66, 260-262, doi: 10. 1161/hypertensionaha. 115. 05093 (2015).
11. Yamamoto, K., Chappell, M. C., Brosnihan, K. B. , Ferrario, C. M. In vivo metabolism of angiotensin I by neutral endopeptidase (EC 3. 4. 24. 11) in spontaneously hypertensive rats. Hypertension 19, 692-696, doi: 10. 1161/01. hyp. 19. 6. 692 (1992).
12. Chappell, M. C. Biochemical evaluation of the renin-angiotensin system: The good, bad, and absolute American Journal of Physiology-Heart and Circulatory Physiology 310, H137-H152, doi: 10. 1152/ajpheart. 00618. 2015 (2016).
13. Ferrario, C. M., et al. Effect of Angiotensin-Converting Enzyme Inhibition and Angiotensin II Receptor Blockers on Cardiac Angiotensin-Converting Enzyme 2. Circulation 111, 2605 (2005).
14. Wysocki, J., et al. ACE and ACE2 activity in diabetic mice. Diabetes 55, 2132-2139, doi: 10. 2337/db06-0033 (2006).
15. Elased, K. M., Cunha, T. S., Gurley, S. B., Coffman, T. M. , Morris, M. New Mass Spectrometric Assay for Angiotensin-Converting Enzyme 2 Activity. Hypertension 47, 1010-1017, doi: 10. 1161/01. hyp. 0000215588. 38536. 30 (2006).
16. Trask, A. J., et al. Inhibition of Angiotensin-Converting Enzyme 2 Exacerbates Cardiac Hypertrophy and Fibrosis in Ren-2 Hypertensive Rats. American Journal of Hypertension 23, 687-693, doi: 10. 1038/ajh. 2010. 51 (2010).
17. Varagic, J., Ahmad, S., Nagata, S. , Ferrario, C. M. ACE2: Angiotensin II/Angiotensin-(1-7) Balance in Cardiac and Renal Injury. Current Hypertension Reports 16, 1-9, doi: 10. 1007/s11906-014-0420-5 (2014).
18. Grobe, J. L., et al. Prevention of angiotensin II-induced cardiac remodeling by angiotensin-(1-7). American Journal of Physiology-Heart and Circulatory Physiology 292, H736-H742, doi: 10. 1152/ajpheart. 00937. 2006 (2007).
19. Santos, R. A. S., Ferreira, A. J., Verano-Braga, T. , Bader, M. Angiotensin-converting enzyme 2, angiotensin-(1-7) and Mas: New players of the renin-angiotensin system. Journal of Endocrinology 216, R1-R17, doi: 10. 1530/joe-12-0341 (2013).
20. Shariat-Madar, Z., Mahdi, F. , Schmaier, A. H. Identification and characterization of prolylcarboxypeptidase as an endothelial cell prekallikrein activator. J Biol Chem 277, 17962-17969, doi: 10. 1074/jbc. M106101200 (2002).
21. Maier, C., et al. Prolylcarboxypeptidase deficiency is associated with increased blood pressure, glomerular lesions, and cardiac dysfunction independent of altered circulating and cardiac angiotensin II. Journal of Molecular Medicine, 1-14, doi: 10. 1007/s00109-017-1513-9 (2017).
22. Welches, W. R., Bridget Brosnihan, K. , Ferrario, C. M. A comparison of the properties and enzymatic activities of three angiotensin processing enzymes: Angiotensin converting enzyme, prolyl endopeptidase and neutral endopeptidase 24. 11. Life Sciences 52, 1461-1480, doi: 10. 1016/0024-3205(93)90108-F (1993).
23. Serfozo P. D., W. J., Ye, M. , Batlle, D. Massive formation of ang(1-7) from angII(1-8) is largely ace2 independent [Abstract]. J Am Soc Nephrol. 26, 699A-700A (2015).
24. Yamada, K., Iyer, S. N., Chappell, M. C., Ganten, D. , Ferrario, C. M. Converting Enzyme Determines Plasma Clearance of Angiotensin-(1-7). Hypertension 32, 496-502, doi: 10. 1161/01. hyp. 32. 3. 496 (1998).
25. Chappell, M., Marshall, A., Alzayadneh, E., Shaltout, H. , Diz, D. Update on the Angiotensin Converting Enzyme 2-Angiotensin (1-7)-Mas Receptor Axis: Fetal Programing, Sex Differences, and Intracellular Pathways. Frontiers in Endocrinology 4, doi: 10. 3389/fendo. 2013. 00201 (2014).
26. Grobe, N., Elased, K. M., Cool, D. R. , Morris, M. Mass spectrometry for the molecular imaging of angiotensin metabolism in kidney. American Journal of Physiology-Endocrinology And Metabolism 302, E1016 (2012).
27. Keidar, S., Strizevsky, A., Raz, A. , Gamliel-Lazarovich, A. ACE2 activity is increased in monocyte-derived macrophages from prehypertensive subjects. Nephrology Dialysis Transplantation 22, 597-601, doi: 10. 1093/ndt/gfl632 (2007).
28. Levy, A., et al. ACE2 expression and activity are enhanced during pregnancy. American Journal of Physiology-Regulatory, Integrative and Comparative Physiology 295, R1953-R1961, doi: 10. 1152/ajpregu. 90592. 2008 (2008).
29. Yamaleyeva, L. M., Shaltout, H. A. , Varagic, J. Apelin-13 in blood pressure regulation and cardiovascular disease. Current Opinion in Nephrology and Hypertension 25, 396-403, doi: 10. 1097/mnh. 0000000000000241 (2016).
30. Kalea, A. Z. , Batlle, D. Apelin and ACE2 in cardiovascular disease. Curr Opin Investig Drugs 11, 273-282 (2010).
31. Vickers, C., et al. Hydrolysis of biological peptides by human angiotensin-converting enzyme-related carboxypeptidase. J Biol Chem 277, 14838-14843, doi: 10. 1074/jbc. M200581200 (2002).
32. Oudit, G. Y., Crackower, M. A., Backx, P. H. , Penninger, J. M. The role of ACE2 in cardiovascular physiology. Trends Cardiovasc Med 13, 93-101 (2003).
33. Ye, M., et al. Murine recombinant angiotensin-converting enzyme 2: Effect on angiotensin II-dependent hypertension and distinctive angiotensin-converting enzyme 2 inhibitor characteristics on rodent and human angiotensin-converting enzyme 2. Hypertension 60, 730-740, doi: 10. 1161/HYPERTENSIONAHA. 112. 198622 (2012).
34. Carrera, E., Linares, A., Joachim, A., Jean-Baptiste, M. , Speth, R. MCA-APK(Dnp) is not a selective substrate of angiotensinconverting enzyme-2 (1067. 6). The FASEB Journal 28 (2014).
35. Lambert, D. W., et al. Tumor necrosis factor-alpha convertase (ADAM17) mediates regulated ectodomain shedding of the severeacute respiratory syndrome-coronavirus (SARS-CoV) receptor, angiotensin-converting enzyme-2 (ACE2). J Biol Chem 280, 30113-30119, doi: 10. 1074/jbc. M505111200 (2005).
36. Wysocki, J., et al. Regulation of urinary ACE2 in diabetic mice. American Journal of Physiology-Renal Physiology 305, F600-F611, doi: 10. 1152/ajprenal. 00600. 2012 (2013).
37. Lew, R. A., et al. Angiotensin-converting enzyme 2 catalytic activity in human plasma is masked by an endogenous inhibitor. Experimental Physiology 93, 685-693, doi: 10. 1113/expphysiol. 2007. 040352 (2008).
38. Gembardt, F., et al. Organ-specific distribution of ACE2 mRNA and correlating peptidase activity in rodents. Peptides 26, 1270-1277, doi: 10. 1016/j. peptides. 2005. 01. 009 (2005).
39. Garabelli, P. J., Modrall, J. G., Penninger, J. M., Ferrario, C. M. , Chappell, M. C. Distinct roles for angiotensin-converting enzyme 2 and carboxypeptidase A in the processing of angiotensins within the murine heart. Experimental Physiology 93, 613-621, doi: 10. 1113/expphysiol. 2007. 040246 (2008).
40. Santos, R. A. S., et al. Angiotensin-(1-7) is an endogenous ligand for the G protein-coupled receptor Mas. Proceedings of the National Academy of Sciences 100, 8258-8263, doi: 10. 1073/pnas. 1432869100 (2003).
41. Ferrario, C. M. ACE2: More of Ang-(1-7) or less Ang II Current Opinion in Nephrology and Hypertension 20, 1-6, doi: 10. 1097/MNH. 0b013e3283406f57 (2011).
42. Trask, A. J., Averill, D. B., Ganten, D., Chappell, M. C. , Ferrario, C. M. Primary role of angiotensin-converting enzyme-2 in cardiac production of angiotensin-(1-7) in transgenic Ren-2 hypertensive rats. American Journal of Physiology-Heart and Circulatory Physiology 292, H3019-H3024, doi: 10. 1152/ajpheart. 01198. 2006 (2007).
43. Gwathmey, T. M., et al. Angiotensin-(1-7)-Angiotensin-Converting Enzyme 2 Attenuates Reactive Oxygen Species Formation to Angiotensin II Within the Cell Nucleus. Hypertension 55, 166-171, doi: 10. 1161/hypertensionaha. 109. 141622 (2010).
44. Velez, J. C. Prolyl carboxypeptidase: A forgotten kidney angiotensinase. Focus on "Identification of prolyl carboxypeptidase as an alternative enzyme for processing of renal angiotensin II using mass spectrometry". Am J Physiol Cell Physiol 304, C939-940, doi: 10. 1152/ajpcell. 00081. 2013 (2013).
45. Lawandi, J., Gerber-Lemaire, S., Juillerat-Jeanneret, L. , Moitessier, N. Inhibitors of prolyl oligopeptidases for the therapy of human diseases: Defining diseases and inhibitors. J Med Chem 53, 3423-3438, doi: 10. 1021/jm901104g (2010).
46. Welches, W. R., et al. Evidence that prolyl endopeptidase participates in the processing of brain angiotensin. J Hypertens 9, 631-638 (1991).
47. Grobe, N., et al. Identification of prolyl carboxypeptidase as an alternative enzyme for processing of renal angiotensin II using mass spectrometry. American Journal of Physiology-Cell Physiology 304, C945-C953, doi: 10. 1152/ajpcell. 00346. 2012 (2013).
48. Wysocki, J., et al. Targeting the Degradation of Angiotensin II With Recombinant Angiotensin-Converting Enzyme 2: Prevention of Angiotensin II-Dependent Hypertension. Hypertension 55, 90-98, doi: 10. 1161/hypertensionaha. 109. 138420 (2010).